Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Policymakers Rolling Up Their Sleeves to Embody Drug Pricing Overhaul
January 1, 2017
-
REGULATORY AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support
December 28, 2016
-
BUSINESS 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
December 27, 2016
-
ORGANIZATION Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
December 26, 2016
-
BUSINESS Sumitomo Dainippon to Buy US Hematology Startup Tolero
December 22, 2016
-
BUSINESS Ono Slashes Opdivo Sales Outlook on 50% Price Cut
December 22, 2016
-
REGULATORY Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
December 21, 2016
-
BUSINESS New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
December 21, 2016
-
REGULATORY Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
-
REGULATORY Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
-
BUSINESS Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
-
ACADEMIA New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
-
BUSINESS Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
December 16, 2016
-
BUSINESS Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
December 16, 2016
-
ORGANIZATION JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
-
REGULATORY PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
-
REGULATORY MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
-
REGULATORY Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
-
BUSINESS Aspen Japan Starting on Right Foot on AG Biz: GSK Japan President
December 13, 2016
-
REGULATORY Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…